NASDAQ: PALIPalisade Bio Inc Stock
$1.13-0.03 (-2.59%)
Updated Nov 6, 2026
PALI Price
$1.13
Fair Value Price
$2.39
Market Cap
$196.93M
52 Week Low
$1.08
52 Week High
$2.86
P/E
1.88x
P/B
1.62x
P/S
881.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$500.00k
Earnings
-$31.94M
Gross Margin
100%
Operating Margin
-6,386.6%
Profit Margin
-6,388.2%
Debt to Equity
0.05
Operating Cash Flow
-$18M
Beta
1.21
Next Earnings
Nov 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PALI Overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PALI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PALI
Ranked#277 of 449
Ranked#277 of 449
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $904.35 | A | |
| $15.20 | A | |
| $8.25 | A |
Be the first to know about important PALI news, forecast changes, insider trades & much more!
PALI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PALI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PALI ($1.13) is undervalued by 52.81% relative to our estimate of its Fair Value price of $2.39 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PALI ($1.13) is significantly undervalued by 52.81% relative to our estimate of its Fair Value price of $2.39 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PALI was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PALI due diligence checks available for Premium users.
Valuation
PALI fair value
Fair Value of PALI stock based on Discounted Cash Flow (DCF)
Price
$1.13
Fair Value
$2.39
Undervalued by
52.81%
PALI ($1.13) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PALI ($1.13) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PALI was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PALI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.88x
Industry
17.77x
Market
39.38x
PALI is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PALI is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PALI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.62x
Industry
5.19x
PALI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PALI's financial health
Profit margin
Revenue
$500.0k
Net Income
-$10.6M
Profit Margin
-2,114.8%
PALI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PALI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$127.3M
Liabilities
$5.6M
Debt to equity
0.05
PALI's short-term assets ($127.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PALI's short-term assets ($127.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PALI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PALI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.6M
Investing
$0.0
Financing
$147.0k
PALI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PALI vs Biotech Stocks
Palisade Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.